Humacyte (NASDAQ:HUMAW – Get Free Report) is expected to release its results before the market opens on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.0980) per share and revenue of $1.1190 million for the quarter.
Humacyte Stock Up 2.4%
HUMAW stock opened at $0.01 on Tuesday. The firm’s 50-day simple moving average is $0.02 and its 200 day simple moving average is $0.07. Humacyte has a fifty-two week low of $0.00 and a fifty-two week high of $0.41.
Humacyte Company Profile
Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.
Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.
See Also
- Five stocks we like better than Humacyte
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
